RGT
Argent Biopharma Limited
🇦🇺 ASX
📦 LOGISTICS
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 128.57%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
7
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Argent Biopharma Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2006-12-21. Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.
📈 Performance
Price History
+3614.29%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.26
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in RGT
7
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in RGT
123 days
RGT investor breakdown
💵 Income of investors
More than 200k
150k - 200k
14%
100k - 150k
29%
50k - 100k
43%
Less than 50k
14%
👶 Age of investors
18 - 25
26 - 34
29%
35 - 90
71%
🙋 Legal gender of investors
Female
43%
Male
57%
Pearlers who invest in RGT also invest in...
MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its central business strategy revolves around the development and supply of medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia. The company maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products in the developmental stages. Its clinical trials include CannEpil, CimetrA and ArtemiC. The company has a growing patient base in Australia, the United Kingdom, Brazil, and Ireland. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.
🙌 Performance (5Yr p.a)
220.00%
📊 Share price
$0.42 AUD
📦 LOGISTICS
MGC Pharmaceuticals Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. MGC Pharmaceuticals Ltd is an Australia-based biopharma company. The firm is primarily focused on the development and supply of standardized phytomedicines to patients globally. The company has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy; CogniCann, in a Phase II trial for symptomatic relief of Dementia, and Irnican, a preclinical medicine to be used for treatment for Glioblastoma. The firm is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. The company has a product offering targeting two medical conditions, which include epilepsy and dementia. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.
📊 Share price
$0.42 AUD
NULL STOCK
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
12.86%
📊 Share price
$129.54 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
🙌 Performance (5Yr p.a)
24.88%
📊 Share price
$45.04 AUD
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.71%
📊 Share price
$66.50 AUD
⛳️ DIVERSIFIED
🌏 GLOBAL
Want more shares? Try these...
Ramsay Health Care Ltd. engages in the healthcare services and the operation of hospitals and day surgery facilities. The company is headquartered in Sydney, New South Wales and currently employs 89,000 full-time employees. The Company’s segments include Asia Pacific, UK, France and Nordics. Its businesses include Ramsay Australia, Ramsay Sante, Ramsay UK, and Elysium Healthcare. Ramsay Australia has over 73 private hospitals and day surgery units in Australia. Ramsay Sante is a private care provider in Europe and operates 443 multidisciplinary hospitals and clinics and 130 primary care centers across five countries. Ramsay UK has a network of 34 acute hospitals and day procedure centers in England providing a comprehensive range of clinical specialties to private and self-insured patients. Elysium Healthcare is an independent sector provider of specialist health and care services. Its four core service streams are mental health, neurological, learning disabilities and children and education.
🙌 Performance (5Yr p.a)
-8.66%
📊 Share price
$39.27 AUD
🩺 HEALTH CARE
🍃 HIGH ESG SCORE
🌳 ENVIRONMENTAL
🕊️ SOCIALLY AWARE
Ramsay Health Care Ltd. engages in the healthcare services and the operation of hospitals and day surgery facilities. The company is headquartered in Sydney, New South Wales and currently employs 89,000 full-time employees. The Company’s segments include Asia Pacific, UK, France and Nordics. Its businesses include Ramsay Australia, Ramsay Sante, Ramsay UK, and Elysium Healthcare. Ramsay Australia has over 73 private hospitals and day surgery units in Australia. Ramsay Sante is a private care provider in Europe and operates 443 multidisciplinary hospitals and clinics and 130 primary care centers across five countries. Ramsay UK has a network of 34 acute hospitals and day procedure centers in England providing a comprehensive range of clinical specialties to private and self-insured patients. Elysium Healthcare is an independent sector provider of specialist health and care services. Its four core service streams are mental health, neurological, learning disabilities and children and education.
🙌 Performance (5Yr p.a)
-0.25%
📊 Share price
$105.98 AUD
🩺 HEALTH CARE
🌳 ENVIRONMENTAL
🍃 HIGH ESG SCORE
💰 HIGH DIVIDEND
🕊️ SOCIALLY AWARE
RGN
Region Group engages in the business of investing in and managing shopping centres. The company is headquartered in Sydney, New South Wales. The company went IPO on 2012-11-26. The firm is engaged in investing in a geographically diverse portfolio of convenience-based retail centers located across Australia. Its portfolio focuses on the non-discretionary retail sector (primarily convenience retailers and grocery outlets) and is anchored by long-term leases to tenants. The firm owns and manages approximately 92 convenience-based retail properties. The Company’s properties include Albury, Annandale Central, Auburn Central, AYR (Burdekin Plaza), Bakewell, Belmont Central, Bentons Square, Blakes Crossing, Brookwater Village, Burnie Plaza, Bushland Beach, Busselton, Cabarita, Cardiff, Central Highlands (Emerald), Chancellor Park Marketplace, Claremont Plaza, Cooloola Cove, Currambine Central, Delacombe Town Centre, Drayton Central, and Bentons Square, among others.
🙌 Performance (5Yr p.a)
-3.91%
📊 Share price
$2.18 AUD
🌳 ENVIRONMENTAL
🏠 REAL ESTATE
RGOS.AX was created on 2024-04-12 by Russell. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform the Funds benchmark, before costs and tax, over the long term by providing exposure to a diversified portfolio of predominantly international shares.
📊 Share price